WO2018136917A1 - Potassium channel modulators - Google Patents
Potassium channel modulators Download PDFInfo
- Publication number
- WO2018136917A1 WO2018136917A1 PCT/US2018/014792 US2018014792W WO2018136917A1 WO 2018136917 A1 WO2018136917 A1 WO 2018136917A1 US 2018014792 W US2018014792 W US 2018014792W WO 2018136917 A1 WO2018136917 A1 WO 2018136917A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disease
- compound
- mmol
- condition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- potassium channels are the most prevalent and diverse, being found in a variety of animal cells such as nervous, muscular, glandular, immune, reproductive, and epithelial tissue. These channels allow the flow of potassium in and/or out of the cell under certain conditions. These channels are regulated, e.g., by calcium sensitivity, voltage-gating, second messengers, extracellular ligands, and ATP-sensitivity.
- the small conductance calcium-activated potassium channels are a subfamily of Ca 2+ -activated K + channels and the SK channel family contains 4 members - SKI, SK2, SK3, and SK4 (often referred to as intermediate conductance).
- the physiological roles of the SK channels have been especially studied in the nervous system, where for example they are key regulators of neuronal excitability and of neurotransmitter release, and in smooth muscle, where they are crucial in modulating the tone of vascular, broncho- tracheal, urethral, uterine or gastro-intestinal musculature.
- FIG. 1 is a diagram illustrating the effect of Compound 1 following oral (PO) dosing on harmaline induced tremor.
- FIG. 2 displays the efficacy and dose response of Compound 1 in percent motion power.
- FIG. 3 shows the effects of Compound 1 on Purkinje cell firing irregularity in ex vivo slices from SCA2 58Q transgenic mice.
- FIG. 4 shows the effects of Compound 1 on baseline ataxia in the EA2 Tottering mouse model.
- the terms "subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and laboratory animals (e.g., rats, mice, guinea pigs and the like).
- the subject is a human in need of treatment.
- the stereochemistry of a disclosed compound is named or depicted by structure
- the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to all of the other stereoisomers.
- Percent by weight pure relative to all of the other stereoisomers is the ratio of the weight of one stereoisiomer over the weight of the other stereoisomers.
- the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure.
- Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer.
- salts of the compounds refer to nontoxic "pharmaceutically acceptable salts.”
- Pharmaceutically acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
- Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.
- Pharmaceutically acceptable acidic/anionic salts include, e.g., the acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, carbonate, citrate, dihydrochloride, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, malate, maleate, malonate, mesylate, nitrate, salicylate, stearate, succinate, sulfate, tartrate, and tosylate.
- compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose- based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxy
- treatment refers to reversing, alleviating, reducing the likelihood of developing, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
- treatment may be administered after one or more symptoms have developed, i.e., therapeutic treatment.
- treatment may be administered in the absence of symptoms.
- treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors), i.e., prophylactic treatment. Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
- an effective amount or “therapeutically effective amount” includes an amount of a compound described herein that will elicit a biological or medical response of a subject.
- compounds and compositions described herein are useful in treating diseases and/or disorders associated with the activity of potassium channels.
- diseases and/or disorders include e.g., neurodegenerative and neurological conditions (e.g., Parkinson's disease, tremors, Alzheimer's disease, dementia, amyotrophic lateral sclerosis (ALS) ataxia, anxiety, depression, mood disorders, memory and attention deficits, bipolar disorder, psychosis, schizophrenia, traumatic brain injury, and narcolepsy), heart disease and related conditions (e.g., ischaemic heart disease, coronary heart disease, angina pectoris, and coronary artery spasms), metabolic disease and bladder diseases (e.g., bladder spasms, urinary incontinence, bladder outflow obstruction, gastrointestinal dysfunction, irritable bowel syndrome, and diabetes), withdrawal symptoms associated with termination of addiction, and other conditions associated with the modulation of potassium channels such as e.g., respiratory diseases, epilepsy, convulsions, seizures, absence seizures,
- the present disclosure also provides a method of modulating the activity of a potassium channel in a subject comprising the step of administering a compound described herein.
- the present disclosure provides a method of positively modulating a SK2 channel in a cell comprising the step of contacting the cell with a compound described herein.
- the provided compounds and compositions are used to treat tremors.
- Tremors include, but are not limited to rest, active, postural, kinetic, intention, task specific, and idiopathic tremors.
- the provided compounds and compositions are used to treat postural and active tremors. Examples of postural and/or active tremors include essential tremor, drug-induced parkinsonism, neuropathic tremor, and tremors induced from toxins (e.g., alcohol withdrawal or from exposure to heavy metals).
- the provided compounds and compositions are used to treat essential tremor.
- the present disclosure further provides a method of treating essential tremor in a subject comprising the step of administering a compound or pharmaceutically acceptable salt or composition described herein.
- Essential tremor is one of the most common neurological disorders, affecting -0.9% of the general population.
- Essential tremor is characterized by an action tremor of the upper limbs and, less commonly, the head, voice, and trunk.
- a family history of essential tremor can be identified in approximately half of patients, suggesting a genetic component. Drinking alcohol often temporarily reduces tremor.
- the present disclosure provides a method of treating a disease or condition selected from a neurodegenerative disease, dementia, heart disease, withdrawal symptoms associated with termination of addiction, metabolic disease, and bladder disease.
- a disease or condition selected from ataxia, dystonia, Parkinson's disease, ischemia, traumatic brain injury, amyotrophic lateral sclerosis, hypertension, atherosclerosis, diabetes,
- the present disclosure provides a method of treating ataxia. In some embodiments, the present disclosure provides a method of treating spinocerebellar ataxia. [0026]
- the present disclosure provides pharmaceutically acceptable compositions comprising a compound described herein; and a pharmaceutically acceptable carrier. These compositions can be used to treat one or more of the diseases and conditions described above.
- compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra- articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- Liquid dosage forms, injectable preparations, solid dispersion forms, and dosage forms for topical or transdermal administration of a compound are included herein.
- provided compounds that may be combined with carrier materials to produce a composition in a single dosage form will vary depending upon the patient to be treated and the particular mode of administration. In some embodiments, provided
- compositions may be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the provided compound, such as e.g., 0.1 - 100 mg/kg body weight/day, can be administered to a patient receiving these compositions.
- a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, the judgment of the treating physician, and the severity of the particular disease being treated.
- the amount of a provided compound in the composition will also depend upon the particular compound in the composition.
- 1H NMR exhibited, via integration, 3 proton resonances in the aromatic region and 1 broad resonance corresponding to the exchangeable proton at N-18.
- the aromatic protons were observed as two doublets and a singlet, indicating two adjacent protons, and one isolated aromatic proton.
- resonances corresponding to 20 protons were observed, showing 1 distinct singlet. Integration of these resonances corresponded to two upfield doublet-doublet resonances, one with a partially overlapping multiplet proton, and four downfield multiplets, two of which partially overlap.
- the upfield aliphatic multiplets are associated with the morpholine moiety of the structure.
- the downfield multiplets are split additionally by the proximity of CF 2 to these protons.
- 13 C NMR data revealed 14 separate carbon resonances and were generated from a decoupled 13 C carbon spectrum acquired at 25 °C in CDC1 3 .
- the 14 resonances are consistent with the structure of 1 in which four pairs of the 18 carbons are spectroscopic ally equivalent.
- One carbon resonance (C-12 at 77.05 ppm) was observed to be partially obscured by the CHCI 3 resonance in the spectrum.
- the presence of a carbon at this resonance was confirmed by collection of a 13 C spectrum in C 6 D6; a resonance at 79.7 ppm was observed without interference from the solvent peak, in addition to all other resonances observed.
- Each of the triplets observed are consistent with F2 substitution at C-22, and decreasing coupling constant with respect to fluorine as the number of intervening bonds increase.
- reaction was heated to 60 °C, and completion of reaction was determined by TLC and UPLC. After 5 h, the reaction mixture was concentrated under reduced pressure and the residue was diluted with ethyl acetate, washed with water, and washed with brine solution.
- the reaction mixture was cooled to room temperature, filtered, and the solid was washed with ethyl acetate (500 mL). The filtrate was washed with water (2 x 100 mL), brine (100 mL), dried over sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography (60-120 silica gel) eluted with 15% EtOAc in hexane.
- reaction mixture was degassed using argon gas for 5-10 min, followed by addition of bis(triphenylphosphine)palladium(II) dichloride (0.2 g, 0.28 mmol, 0.02 eq).
- the reaction mixture was sealed and heated at 80 °C for 16 h (completion of reaction was determined by LCMS) and cooled to room temperature.
- the reaction mixture was diluted with water (300 mL) and extracted with ethyl acetate (2 x 150 mL). The combined organics were dried over sodium sulfate, filtered, and evaporated to afford a crude product as a light brown sticky solid.
- reaction mixture was concentrated to remove acetone, diluted with ice cold water (100 mL), basified with saturated sodium by carbonate solution, and extracted with ethyl acetate (2 x 100 mL). The combined organics were dried over sodium sulfate, filtered, and evaporated under reduced pressure to afford a crude product as a light brown sticky solid.
- reaction mixture was slowly warmed to rt and stirred at same temperature for 6 hours. The completion of reaction was determined by TLC and UPLC. The reaction mixture was concentrated and the resulting residue was quenched with 10% saturated sodium bicarbonate solution, extracted with ethyl acetate (2x100 mL), and concentrated under reduced pressure to afford crude product. The crude product was purified through column chromatography using 60-120 silica gel, ethyl acetate-pet ether as solvent system. The resulting solid was dried under vacuum to afford 2- (3-cyclopropyl-lH-pyrazol-l-yl)-N-(4,4-difluorocyclohexyl)-6-morpholinopyrimidin-4- amine 7 (0.73g, 90%).
- a compound is defined to be an SK Positive Allosteric Modulator (PAM) if the compound increases current in this assay, for example, if the SCioo value of the compound is less than or equal to 10 ⁇ as determined by this assay.
- the SCioo value is defined to be the concentration of compound that increases the basal current by 100%.
- the signal was filtered with a 128-ms unweighted moving average filter, and events with amplitudes > 0.5 V and lasting > 300 ms in duration were counted as a tremor event.
- Data were analyzed in one-minute bins over the course of the test and presented as the sum of tremor events over the entire 60 minute test. As shown by FIG. 1, significant inhibition of tremors was observed at a dose of 30 mg/Kg Compound I.
- %MP percent Motion Power
- C FB is the amount of free compound not complexed with protein and therefore free to interact with the SK2 channel (Table 1, "Calculated Free Brain Concentration”).
- BFF is average free fraction of compound as measured by equilibrium dialysis in separate experiments (1 uM test concentration incubated in 10% rat brain tissue homogenate for 5 hours at 37 C C) (Table 1, "Brain Free Fraction”). Free drug in brain available to interact with SK2 channels (C FB) is arrived at by multiplying the measured total brain level (C MB ) by the average free fraction (BFF).
- %SK2 SCioo C FB /SK2 SCioo 100, where SK2 SCioo (Table 1, "SK2 SCioo") is the measured value of potency of the compound on SK2 channels and %SK2 SCioo (Table 1, "%SK2 SCioo") is the free brain concentration (C FB ) normalized to SK2 SCioo- Values are given in Table 1.
- Compound 1 has demonstrated efficacy in validated animal models of hereditary ataxia (EA2) and ET (harmaline-induced tremor). To test whether Compound 1 can alleviate ataxia in a disease model, it was evaluated in the EA2 "Tottering" mouse model. These mice display a basal ataxia that arises from irregularity in Purkinje cell pacemaker firing due to a loss-of-function mutation in P/Q Ca 2+ channels (the same protein that is mutated in SCA6), which causes Episodic Ataxia 2 (EA2). Animals were assessed in the parallel rod floor apparatus which automatically counts the number of times the animal's foot slips through the evenly spaced metal rods and the total distance the animal travels.
- EA2 hereditary ataxia
- ET aline-induced tremor
- Ataxia Ratio Baseline ataxia was then expressed as the Ataxia Ratio, which is the total number of foot slips divided by the total distance the animal travels in centimeters.
- the increase in Ataxia Ratio between wild-type and EA2 mice is illustrated in FIG. 4.
- Aqueous solubility (kinetic solubility) tests of the compounds were performed in phosphate buffer saline (pH 7.4) measured by shake-flask method.
- DMSO stock solution of test compound is added to buffer followed by equilibration (shaking), filtration and determination of soluble amount by HPLC-UV Conditions used in the assay are summarized below. Results are shown in Table 2 and Table 3.
- Aqueous buffer 0.05M Phosphate Buffer System pH 7.4
- HPLC-UV Reference compounds Caffeine (high solubility) and Diethylstilbestrol (low solubility)
- test compound is incubated with liver microsomes in the presence of NADPH for 2 time points at 37°C. At the end of incubation, reaction is quenched with acetonitrile containing internal standard and the parent compound remaining is determined by LC-MS/MS. Conditions used in the assay are summarized below. Results are shown in Table 2.
- Liver microsome protein concentration in assay 0.5mg/ml
- Test drug (Inhibitor) Concentration 8 different concentrations ( ⁇ to 0.005 ⁇ )
- hERG cardiac potassium channel hERG assay.
- hERG is responsible for a rapid delayed rectifier current ( ⁇ ) in human ventricles.
- Inhibition of I & is the most common cause of cardiac action potential prolongation by non-cardiac drugs. See e.g., Brown, A.M. and Rampe, D. (2000). Drug-induced long QT syndrome: is HERG the root of all evil? Pharmaceutical News 7, 15-20.
- HEK-293 cells were stably transfected with hERG cDNA. Stable transfectants were selected by coexpression with the G418-resistance gene incorporated into the expression plasmid. Selection pressure was maintained by including G418 in the culture medium.
- Cells were cultured in Dulbecco' s Modified Eagle Medium / Nutrient Mixture F-12 (D-MEM/F-12) supplemented with 10% fetal bovine serum, 100 U/mL penicillin G sodium, 100 ⁇ g/mL streptomycin sulfate and 500 ⁇ g/mL G418. Cell culture records are kept on file at Charles River Laboratories.
- Onset and steady state inhibition of hERG current was measured using a pulse pattern with fixed amplitudes (conditioning prepulse: +20 mV for 2 s; test pulse: -50 mV for 2 s) repeated at 10 s intervals, from a holding potential of -80 mV. Peak tail current was measured during the 2 s step to -50 mV.
- Rat strain/sex Sprague Dawley/Male Age / body weight: 6 to 8 weeks/ 250-300gms
- Dosing volume Intravenous (2ml/kg) & Oral (lOml/kg)
- Formulation vehicles Standard formulations or suggested by Sponsor
- Dose levels IV & Oral: lmg/kg; intravenous & lOmg/kg; oral or as suggested
- Anti-coagulant 0.2% K2 EDTA
- SC 100 Concentration that produces doubling of channel current
- Compound 1 also has better solubility, higher BFF, higher microsomal stability, and greater oral bioavailability than Comparator A.
- An overall improvement in BFF and solubility over Comparator A and phenyl derivative Comparator C was also demonstrated across the compounds described herein as shown in Table 3. Compound 1 is reproduced from above for ease of comparison.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
Priority Applications (23)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RS20220119A RS62899B1 (sr) | 2017-01-23 | 2018-01-23 | Modulatori kalijumovih kanala |
| MYPI2019003912A MY195123A (en) | 2017-01-23 | 2018-01-23 | Potassium Channel Modulators |
| ES18704122T ES2906078T3 (es) | 2017-01-23 | 2018-01-23 | Moduladores del canal de potasio |
| HRP20220079TT HRP20220079T1 (hr) | 2017-01-23 | 2018-01-23 | Modulatori kalijevih kanala |
| KR1020197024269A KR102664772B1 (ko) | 2017-01-23 | 2018-01-23 | 칼륨 채널 조절제 |
| LTEPPCT/US2018/014792T LT3571193T (lt) | 2017-01-23 | 2018-01-23 | Kalio kanalo moduliatoriai |
| CU2019000066A CU24560B1 (es) | 2017-01-23 | 2018-01-23 | N-(4,4-difluorociclohexil)-2-(3-metil-1h-pirazol-1-il)-6-morfolinopirimidin-4-amina útil como modulador de canales de potasio |
| SI201830559T SI3571193T1 (sl) | 2017-01-23 | 2018-01-23 | Modulatorji kalijevega kanalčka |
| SG11201905893WA SG11201905893WA (en) | 2017-01-23 | 2018-01-23 | Potassium channel modulators |
| BR112019014814-0A BR112019014814B1 (pt) | 2017-01-23 | 2018-01-23 | Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio |
| DK18704122.3T DK3571193T3 (da) | 2017-01-23 | 2018-01-23 | Potassium Channel Modulators |
| MX2019008682A MX376080B (es) | 2017-01-23 | 2018-01-23 | Moduladores del canal de potasio |
| EA201991488A EA036668B1 (ru) | 2017-01-23 | 2018-01-23 | Модуляторы калиевых каналов |
| JP2019539923A JP6997197B2 (ja) | 2017-01-23 | 2018-01-23 | カリウムチャネルモジュレーター |
| CN201880007979.1A CN110198935B (zh) | 2017-01-23 | 2018-01-23 | 钾通道调节剂 |
| EP18704122.3A EP3571193B1 (en) | 2017-01-23 | 2018-01-23 | Potassium channel modulators |
| UAA201908610A UA123810C2 (uk) | 2017-01-23 | 2018-01-23 | Модулятори калієвих каналів |
| PL18704122T PL3571193T3 (pl) | 2017-01-23 | 2018-01-23 | Modulatory kanału potasowego |
| ZA2019/04458A ZA201904458B (en) | 2017-01-23 | 2019-07-08 | Potassium channel modulators |
| IL267954A IL267954B (en) | 2017-01-23 | 2019-07-09 | potassium channel modulators |
| PH12019501678A PH12019501678A1 (en) | 2017-01-23 | 2019-07-22 | Potassium channel modulators |
| CONC2019/0009060A CO2019009060A2 (es) | 2017-01-23 | 2019-08-22 | Moduladores del canal de potasio |
| CY20221100176T CY1125463T1 (el) | 2017-01-23 | 2022-03-01 | Διαμορφωτες διαυλου καλιου |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449270P | 2017-01-23 | 2017-01-23 | |
| US62/449,270 | 2017-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018136917A1 true WO2018136917A1 (en) | 2018-07-26 |
Family
ID=61188924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2018/014792 Ceased WO2018136917A1 (en) | 2017-01-23 | 2018-01-23 | Potassium channel modulators |
Country Status (30)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113226466A (zh) * | 2018-10-22 | 2021-08-06 | 科登特治疗公司 | 钾通道调节剂的结晶形式 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017210545A1 (en) * | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3571193B1 (en) | 2017-01-23 | 2021-12-01 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| CN118985622B (zh) * | 2024-07-05 | 2025-12-02 | 云南大学 | 一种吡唑类化合物在防治植物根结线虫中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100212A1 (en) * | 2005-03-22 | 2006-09-28 | Neurosearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
| WO2017210545A1 (en) * | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
Family Cites Families (188)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6059883B2 (ja) | 1978-05-08 | 1985-12-27 | 北興化学工業株式会社 | 農園芸用殺菌剤 |
| GB2183243B (en) | 1985-10-09 | 1990-01-24 | Nippon Oil Co Ltd | Process for preparing oil-soluble nitrogen-containing compounds |
| WO1989011279A1 (en) | 1988-05-16 | 1989-11-30 | Georgia State University Foundation, Inc. | Nucleic acid interacting unfused heteropolycyclic compounds |
| LU87304A1 (fr) | 1988-07-29 | 1990-02-07 | Oreal | Nouveaux derives d'ureylene triamino-2,4,6 pyrimidine oxyde-3,leur preparation et leur utilisation en cosmetique et dermopharmacie |
| JPH02282251A (ja) | 1989-04-24 | 1990-11-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
| DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
| DE4034762A1 (de) | 1990-11-02 | 1992-05-07 | Hoechst Ag | Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
| GB2263639A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substituted pyrimidinones as neurotensin antagonists |
| HU209678B (en) | 1992-06-09 | 1994-10-28 | Richter Gedeon Vegyeszet | Process for producing biologically active eburnamenin-14-carbonyl-amino derivatives and pharmaceutical compositions containing them |
| DK72693D0 (da) | 1993-06-18 | 1993-06-18 | Lundbeck & Co As H | Compounds |
| CA2133355A1 (en) | 1993-10-04 | 1995-04-05 | Itaru Nitta | Method for producing polypeptide |
| AU3785597A (en) | 1996-08-14 | 1998-03-06 | Takeda Chemical Industries Ltd. | Cyclic urea compounds, their production and use as herbicides |
| DE19642863A1 (de) | 1996-10-17 | 1998-04-23 | Bayer Ag | Amide |
| US6117973A (en) | 1997-02-24 | 2000-09-12 | Georgia Tech Research Corp. | PNA monomers with electron donor or acceptor |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
| JPH11282132A (ja) | 1998-03-27 | 1999-10-15 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JP2000072695A (ja) | 1998-08-24 | 2000-03-07 | Sumitomo Pharmaceut Co Ltd | 環状化合物 |
| JP2000075449A (ja) | 1998-08-31 | 2000-03-14 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の現像方法 |
| AU6715200A (en) | 1999-09-04 | 2001-04-10 | Astrazeneca Ab | Amides as inhibitors for pyruvate dehydrogenase |
| AU775102B2 (en) | 1999-09-13 | 2004-07-15 | David M. Swope | Composition and method for decreasing neurologic symptomatology |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| EP1303269B1 (en) | 2000-06-29 | 2005-12-07 | NeuroSearch A/S | Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| AU2002213467A1 (en) | 2000-10-11 | 2002-04-22 | Chemocentryx, Inc. | Modulation of ccr4 function |
| AU3950802A (en) | 2000-12-07 | 2002-06-18 | Cv Therapeutics Inc | Abca-1 elevating compounds |
| MXPA03006268A (es) | 2001-01-16 | 2003-09-22 | Astrazeneca Ab | Compuestos terapeuticos de cromano. |
| CA2434015A1 (en) | 2001-01-16 | 2002-07-18 | Astrazeneca Ab | Therapeutic chroman compounds |
| NZ535574A (en) | 2001-01-16 | 2006-07-28 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
| AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| CZ20032829A3 (cs) * | 2001-04-16 | 2005-03-16 | Tanabe Seiyaku Co., Ltd. | Heterocyklické sloučeniny |
| EP1270551A1 (en) | 2001-06-26 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Urea derivatives with antiproteolytic activity |
| US7378432B2 (en) | 2001-09-14 | 2008-05-27 | Tel Aviv University Future Technology Development L.P. | Glycogen synthase kinase-3 inhibitors |
| US7012077B2 (en) | 2001-12-20 | 2006-03-14 | Hoffmann-La Roche Inc. | Substituted cyclohexane derivatives |
| WO2003075828A2 (en) | 2002-03-11 | 2003-09-18 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| AU2003245669A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| DE60305053T2 (de) | 2002-08-19 | 2006-08-31 | Glaxo Group Ltd., Greenford | Pyrimidinderivate als selektive cox-2-inhibitoren |
| WO2004017920A2 (en) | 2002-08-23 | 2004-03-04 | University Of Connecticut | Novel biphenyl and biphenyl-like cannabinoids |
| GB0311201D0 (en) | 2003-05-15 | 2003-06-18 | Merck Sharp & Dohme | Therapeutic agents |
| US7589092B2 (en) | 2003-06-20 | 2009-09-15 | Koronis Pharmaceuticals, Incorporated | Prodrugs of heteroaryl compounds |
| MXPA06001601A (es) | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
| EP1689722A2 (en) | 2003-10-10 | 2006-08-16 | Bayer Pharmaceuticals Corporation | 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
| EP2264030A1 (en) | 2003-10-17 | 2010-12-22 | Incyte Corporation | Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| BRPI0416853A (pt) | 2003-11-24 | 2007-02-13 | Hoffmann La Roche | pirazolila e imidazolila pirimidinas |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| WO2005095357A2 (en) | 2004-03-30 | 2005-10-13 | Taisho Pharmaceutical Co., Ltd. | Pyrimidine derivatives and methods of treatment related to the use thereof |
| TWI380816B (zh) | 2004-04-13 | 2013-01-01 | Synta Pharmaceuticals Corp | 抑制介白素-12(il-12)生成之二鹽抑制劑 |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| EP1805142A4 (en) | 2004-09-23 | 2009-06-10 | Reddy Us Therapeutics Inc | PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME |
| GB0422556D0 (en) | 2004-10-11 | 2004-11-10 | Syngenta Participations Ag | Novel insecticides |
| EP1655283A1 (en) | 2004-11-08 | 2006-05-10 | Evotec OAI AG | 11beta-HSD1 Inhibitors |
| WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| WO2006065590A2 (en) | 2004-12-16 | 2006-06-22 | Xtl Biopharmaceuticals Inc. | Pyridine and pyrimidine antiviral compositions |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2006077367A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflamation |
| WO2006077366A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| WO2006077364A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
| JP2008527028A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| CA2594665A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Thienopyrroles useful in the treatment of inflammation |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| NZ556248A (en) | 2005-03-14 | 2010-06-25 | Neurosearch As | Pyrazolyl-quinazoline potassium channel modulating agents and their medical use |
| CN101115736A (zh) * | 2005-03-14 | 2008-01-30 | 神经研究公司 | 钾通道调节剂和它们的医药用途 |
| US20090036475A1 (en) | 2005-03-22 | 2009-02-05 | Neurosearch A/S | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use |
| US20060156481A1 (en) | 2005-03-22 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| DE102005025315A1 (de) | 2005-06-02 | 2006-12-14 | Merck Patent Gmbh | Ionische Flüssigkeiten mit niedriger Viskosität |
| US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
| EA015890B1 (ru) | 2005-06-14 | 2011-12-30 | Тайджен Байотекнолоджи Ко. Лтд. | Производные пиримидина |
| ATE489370T1 (de) | 2005-06-14 | 2010-12-15 | Schering Corp | Herstellung und verwendung von verbindungen als aspartylproteasehemmer |
| BRPI0614502A2 (pt) | 2005-07-30 | 2011-03-29 | Astrazeneca Ab | Composto, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto |
| DE102005043165A1 (de) | 2005-09-12 | 2007-03-22 | Merck Patent Gmbh | Metallkomplexe |
| JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
| GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
| FR2892859B1 (fr) | 2005-10-27 | 2008-06-06 | Commissariat Energie Atomique | Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications |
| EP1962892A4 (en) | 2005-11-22 | 2011-10-12 | Univ South Florida | INHIBITION OF CELL PROLIFERATION |
| RU2008128453A (ru) | 2005-12-12 | 2010-01-20 | Дженелабс Текнолоджис, Инк. (Us) | Соединение n-(5-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения |
| BRPI0619733A2 (pt) | 2005-12-12 | 2011-10-11 | Genelabs Tech Inc | compostos antivirais de n-(anel aromático de 6 membros)-amido |
| WO2007071632A2 (en) | 2005-12-20 | 2007-06-28 | Neurosearch A/S | 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases |
| AU2007226582B2 (en) | 2006-03-13 | 2012-07-05 | Revvity Health Sciences, Inc. | Substrates and internal standards for mass spectroscopy detection |
| EP2012769A1 (en) | 2006-05-02 | 2009-01-14 | Rundfeldt, Chris | Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms |
| AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
| FR2904316B1 (fr) | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
| EP2046452A2 (en) | 2006-08-03 | 2009-04-15 | Prosensa Technologies B.V. | Antibiotic composition |
| US20110144140A1 (en) | 2006-09-07 | 2011-06-16 | Eriksen Birgitte L | Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents |
| JP2010505794A (ja) | 2006-10-03 | 2010-02-25 | ノイロサーチ アクティーゼルスカブ | カリウムチャネル調節剤として有用なインダゾリル誘導体 |
| WO2008052861A2 (de) | 2006-10-10 | 2008-05-08 | Proionic Production Of Ionic Substances Gmbh & Co Keg | Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten |
| JP2010510246A (ja) | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | アミド抗ウイルス化合物 |
| WO2008070661A1 (en) | 2006-12-04 | 2008-06-12 | Neurocrine Biosciences, Inc. | Substituted pyrimidines as adenosine receptor antagonists |
| GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| CA2675558A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| WO2008104994A2 (en) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
| US20080221103A1 (en) | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
| EP2142546B1 (en) | 2007-03-28 | 2017-06-07 | Saniona A/S | Purinyl derivatives and their use as potassium channel modulators |
| JP5703432B2 (ja) | 2007-03-28 | 2015-04-22 | ノイロサーチ アクティーゼルスカブ | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| US8633186B2 (en) | 2007-06-08 | 2014-01-21 | Senomyx Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| JP5111039B2 (ja) | 2007-09-27 | 2012-12-26 | 富士フイルム株式会社 | 重合性化合物、重合開始剤、および染料を含有する光硬化性組成物 |
| US9089572B2 (en) | 2008-01-17 | 2015-07-28 | California Institute Of Technology | Inhibitors of p97 |
| EP2250999B1 (en) | 2008-02-08 | 2016-04-13 | Shiseido Company, Ltd. | Skin whitening agent and external preparation for the skin |
| CA2717110A1 (en) | 2008-02-28 | 2009-09-03 | Saint Mary's University | Compounds, complexes and uses thereof |
| WO2009120094A2 (en) | 2008-03-27 | 2009-10-01 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
| EP2280948A1 (en) | 2008-04-09 | 2011-02-09 | Mitsubishi Tanabe Pharma Corporation | Pyrimidine, pyridine and triazine derivatives as maxi-k channel openers. |
| EP2279192B1 (en) | 2008-05-28 | 2013-10-30 | Merck Patent GmbH | Ionic liquids |
| MX2010013682A (es) | 2008-06-11 | 2011-03-15 | Astrazeneca Ab | Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos. |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| DE102008031480A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Salze enthaltend ein Pyrimidincarbonsäure-Derivat |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| EP2331527A1 (en) * | 2008-09-02 | 2011-06-15 | NeuroSearch A/S | Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
| CN101684098A (zh) | 2008-09-24 | 2010-03-31 | 中国科学院上海药物研究所 | 一类5-脂氧酶抑制剂及其制备方法、药物组合物和应用 |
| US8268838B2 (en) | 2008-09-26 | 2012-09-18 | Neurosearch A/S | Substituted purinyl-pyrazole derivatives and their use as potassium channel modulators |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| AR074870A1 (es) | 2008-12-24 | 2011-02-16 | Palau Pharma Sa | Derivados de pirazolo (1,5-a ) piridina |
| WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Egfr 억제제 및 질환 치료방법 |
| JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
| US8377639B2 (en) | 2009-06-26 | 2013-02-19 | University Of Massachusetts | Compounds for modulating RNA binding proteins and uses therefor |
| AU2010270030B2 (en) | 2009-07-08 | 2015-12-24 | Baltic Bio Ab | 1, 2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| WO2011026579A1 (en) | 2009-09-04 | 2011-03-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| WO2011029832A1 (de) | 2009-09-09 | 2011-03-17 | Vifor (International) Ag | Neue thiazol- und oxazol-hepcidin-antagonisten |
| EP2499195B1 (en) | 2009-11-13 | 2020-12-09 | Plastipak Packaging, Inc. | Oxygen scavengers, compositions comprising the scavengers, and artcles made from the compositions |
| FR2954317B1 (fr) | 2009-12-23 | 2012-01-27 | Galderma Res & Dev | Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique |
| AT509266B1 (de) | 2009-12-28 | 2014-07-15 | Univ Wien Tech | Substituierte pyridine und pyrimidine |
| CA2791738C (en) | 2010-03-01 | 2020-06-09 | Gtx, Inc. | Aryl imidazolyl compounds for the treatment of cancer |
| CN103221404B (zh) | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| KR20120018236A (ko) | 2010-07-23 | 2012-03-02 | 현대약품 주식회사 | 치환된 피리미디닐 유도체 및 이의 제조방법 |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| WO2012022487A1 (de) | 2010-08-20 | 2012-02-23 | Grünenthal GmbH | Substituierte cyclische carboxamid- und harnstoff-derivate als liganden des vanilloid-rezeptors |
| PL2609086T3 (pl) * | 2010-08-27 | 2015-07-31 | Gruenenthal Gmbh | Podstawione 2-okso- i 2-tiookso-dihydrochinolino-3-karboksyamidy jako modulatory KCNQ2/3 |
| CN103201891A (zh) | 2010-09-30 | 2013-07-10 | 巴斯夫欧洲公司 | 电解质添加剂 |
| JP2013540145A (ja) | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的cyp11b1阻害剤 |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| EP2655334B1 (en) | 2010-12-22 | 2018-10-03 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| WO2012109343A2 (en) | 2011-02-08 | 2012-08-16 | President And Fellows Of Harvard College | Iron complexes and methods for polymerization |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN102731492B (zh) | 2011-03-30 | 2016-06-29 | 江苏恒瑞医药股份有限公司 | 环己烷类衍生物、其制备方法及其在医药上的应用 |
| WO2012154880A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
| TR201906779T4 (tr) | 2011-05-12 | 2019-05-21 | Proteostasis Therapeutics Inc | Proteostaz regülatörleri. |
| AU2012265219B2 (en) | 2011-05-31 | 2017-02-16 | Merck Patent Gmbh | Compounds containing hydrido-tricyano-borate anions |
| HK1197066A1 (zh) | 2011-06-03 | 2015-01-02 | Massachusetts Institute Of Technology | Z選擇性關環複分解反應 |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| JP2013020223A (ja) | 2011-06-17 | 2013-01-31 | Fujifilm Corp | 高分子フィルム、セルロースエステルフィルム、偏光板、及び液晶表示装置 |
| BR112014004832A2 (pt) | 2011-08-29 | 2017-04-04 | Ptc Therapeutics Inc | compostos antibacterianos e métodos para uso |
| JP5741850B2 (ja) | 2011-09-13 | 2015-07-01 | コニカミノルタ株式会社 | 光学フィルム、それを含む偏光板および液晶表示装置 |
| JP5857713B2 (ja) | 2011-12-15 | 2016-02-10 | コニカミノルタ株式会社 | 光学フィルム、偏光板、及び液晶表示装置 |
| WO2013120040A1 (en) | 2012-02-10 | 2013-08-15 | Children's Medical Center Corporation | Targeted pathway inhibition to improve muscle structure, function and activity in muscular dystrophy |
| DE102012006896A1 (de) | 2012-04-05 | 2013-10-10 | Merck Patent Gmbh | Silikate mit organischen Kationen |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| FR2992317B1 (fr) | 2012-06-22 | 2016-05-13 | Diverchim | Procede de preparation de peptides chiraux |
| US20150197503A1 (en) | 2012-07-27 | 2015-07-16 | Bial-Portela & Cª, S.A. | Process for the synthesis of substituted urea compounds |
| WO2014031681A1 (en) | 2012-08-20 | 2014-02-27 | The University Of Chicago | Inhibiting gram positive bacteria |
| WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| EP2897948B1 (en) | 2012-09-18 | 2016-08-31 | Heptares Therapeutics Limited | Bicyclic aza compounds as muscarinic m1 receptor agonists |
| DE102012021452A1 (de) | 2012-10-31 | 2014-04-30 | Merck Patent Gmbh | Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion |
| WO2014078733A1 (en) | 2012-11-16 | 2014-05-22 | The Regents Of The University Of California | Pictet-spengler ligation for protein chemical modification |
| ES2469290B2 (es) | 2012-12-17 | 2015-01-26 | Ocupharm Diagnostics S.L. | Mejora en la aplicación tópica de fármacos oculares mediante la administración de nucleótidos |
| US9279094B2 (en) | 2012-12-21 | 2016-03-08 | Afton Chemical Corporation | Friction modifiers for use in lubricating oil compositions |
| US9499762B2 (en) | 2012-12-21 | 2016-11-22 | Afton Chemical Corporation | Additive compositions with a friction modifier and a detergent |
| WO2014107622A1 (en) | 2013-01-07 | 2014-07-10 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
| WO2014108487A1 (en) | 2013-01-10 | 2014-07-17 | Universite D'aix-Marseille | P-stereogenic chiral precursor of chiral ligands and use thereof |
| US9487472B2 (en) | 2013-02-26 | 2016-11-08 | President And Fellows Of Harvard College | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer |
| RS62649B1 (sr) | 2013-03-12 | 2021-12-31 | Vertex Pharma | Inhibitori dnk-pk |
| JP2016520552A (ja) | 2013-04-05 | 2016-07-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | Pparアゴニスト |
| JP2016530702A (ja) | 2013-07-02 | 2016-09-29 | メルク、パテント、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツングMerck Patent GmbH | 有機エレクトロルミネッセンス素子 |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| CA2918534A1 (en) | 2013-07-25 | 2015-01-29 | Fondazione Telethon | Inhibitors of fapp2 and uses thereof |
| WO2015013715A2 (en) | 2013-07-26 | 2015-01-29 | Thr Regents Of The University Of California | C-h fluorination of heterocycles with silver (ii) fluoride |
| WO2015031725A1 (en) | 2013-08-30 | 2015-03-05 | President And Fellows Of Harvard College | Transition metal-catalyzed imidation of arenes |
| DE102013016324A1 (de) | 2013-10-04 | 2015-04-09 | Merck Patent Gmbh | Perfluoralkylfluor- oder Perfluoralkylchlorgermanate |
| US10329270B2 (en) | 2013-10-21 | 2019-06-25 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
| WO2015069752A1 (en) | 2013-11-05 | 2015-05-14 | The Regents Of The University Of California | Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using |
| CN103626741A (zh) | 2013-11-26 | 2014-03-12 | 苏州大学 | 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物 |
| CA2930343C (en) | 2013-11-29 | 2021-06-08 | Proionic Gmbh | Method for curing an adhesive using microwave irradiation |
| WO2015084936A1 (en) | 2013-12-04 | 2015-06-11 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| MX358346B (es) | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| WO2016058544A1 (en) | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
| GB201502412D0 (en) | 2015-02-13 | 2015-04-01 | Canbex Therapeutics Ltd | Therapeutic use |
| US10980755B2 (en) | 2015-09-10 | 2021-04-20 | The Regents Of The University Of California | LRH-1 modulators |
| US20170299609A1 (en) | 2016-04-18 | 2017-10-19 | Wright State University | Treatment of amyotrophic lateral sclerosis with sk channel activators |
| US20170355708A1 (en) | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| EP3571193B1 (en) * | 2017-01-23 | 2021-12-01 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| WO2018136918A1 (en) | 2017-01-23 | 2018-07-26 | Cadent Therapeutics, Inc. | Methods for the treatment of tremors by positive modulation of sk channels |
-
2018
- 2018-01-23 EP EP18704122.3A patent/EP3571193B1/en active Active
- 2018-01-23 PL PL18704122T patent/PL3571193T3/pl unknown
- 2018-01-23 MY MYPI2019003912A patent/MY195123A/en unknown
- 2018-01-23 HR HRP20220079TT patent/HRP20220079T1/hr unknown
- 2018-01-23 KR KR1020197024269A patent/KR102664772B1/ko active Active
- 2018-01-23 RS RS20220119A patent/RS62899B1/sr unknown
- 2018-01-23 SI SI201830559T patent/SI3571193T1/sl unknown
- 2018-01-23 SG SG11201905893WA patent/SG11201905893WA/en unknown
- 2018-01-23 EA EA201991488A patent/EA036668B1/ru unknown
- 2018-01-23 AR ARP180100148A patent/AR110770A1/es active IP Right Grant
- 2018-01-23 UA UAA201908610A patent/UA123810C2/uk unknown
- 2018-01-23 JP JP2019539923A patent/JP6997197B2/ja active Active
- 2018-01-23 MX MX2019008682A patent/MX376080B/es active IP Right Grant
- 2018-01-23 BR BR112019014814-0A patent/BR112019014814B1/pt active IP Right Grant
- 2018-01-23 HU HUE18704122A patent/HUE057710T2/hu unknown
- 2018-01-23 CU CU2019000066A patent/CU24560B1/es unknown
- 2018-01-23 WO PCT/US2018/014792 patent/WO2018136917A1/en not_active Ceased
- 2018-01-23 DK DK18704122.3T patent/DK3571193T3/da active
- 2018-01-23 PT PT187041223T patent/PT3571193T/pt unknown
- 2018-01-23 TW TW107102410A patent/TWI751271B/zh active
- 2018-01-23 LT LTEPPCT/US2018/014792T patent/LT3571193T/lt unknown
- 2018-01-23 CN CN201880007979.1A patent/CN110198935B/zh active Active
- 2018-01-23 US US15/877,910 patent/US9975886B1/en active Active
- 2018-01-23 ES ES18704122T patent/ES2906078T3/es active Active
- 2018-03-28 US US15/938,292 patent/US10351553B2/en active Active
-
2019
- 2019-06-04 US US16/431,212 patent/US10717728B2/en active Active
- 2019-07-08 ZA ZA2019/04458A patent/ZA201904458B/en unknown
- 2019-07-09 IL IL267954A patent/IL267954B/en unknown
- 2019-07-19 CL CL2019002031A patent/CL2019002031A1/es unknown
- 2019-07-22 PH PH12019501678A patent/PH12019501678A1/en unknown
- 2019-08-22 CO CONC2019/0009060A patent/CO2019009060A2/es unknown
-
2021
- 2021-01-15 US US17/150,230 patent/US20210380571A1/en not_active Abandoned
-
2022
- 2022-03-01 CY CY20221100176T patent/CY1125463T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006100212A1 (en) * | 2005-03-22 | 2006-09-28 | Neurosearch A/S | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
| WO2017210545A1 (en) * | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
Non-Patent Citations (3)
| Title |
|---|
| BROWN, A.M.; RAMPE, D.: "Drug-induced long QT syndrome: is HERG the root of all evil?", PHARMACEUTICAL NEWS, vol. 7, 2000, pages 15 - 20 |
| HOUGAARD ET AL., BRITISH JOURNAL OF PHARMACOLOGY, vol. 151, 8 May 2007 (2007-05-08), pages 655 - 665 |
| SHARAN K. BAGAL ET AL: "Ion Channels as Therapeutic Targets: A Drug Discovery Perspective", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 3, 14 February 2013 (2013-02-14), pages 593 - 624, XP055245230, ISSN: 0022-2623, DOI: 10.1021/jm3011433 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113226466A (zh) * | 2018-10-22 | 2021-08-06 | 科登特治疗公司 | 钾通道调节剂的结晶形式 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210380571A1 (en) | Potassium channel modulators | |
| EP1490365B1 (en) | Azaindoles as inhibitors of c-jun n-terminal kinases | |
| JP2024514990A (ja) | ヘテロアルキルジヒドロキノリンスルホンアミド化合物 | |
| TWI833805B (zh) | 類法尼醇x(farnesoid x)受體促效劑及其用途 | |
| JP2022500391A (ja) | ファルネソイドx受容体アゴニストおよびその使用 | |
| JP6851825B2 (ja) | 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体 | |
| JP2010513285A (ja) | タンパク質キナーゼ阻害剤として有用な化合物 | |
| JP2009538309A (ja) | プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド | |
| RS56012B1 (sr) | Derivati bipirazola kao inhibitori jak | |
| CN113045551B (zh) | 一种作为甲状腺激素β受体激动剂的化合物及其用途 | |
| RS63021B1 (sr) | Novi derivati benzamida kao ppar-gama modulatori | |
| US20250000854A1 (en) | 4-(Aminomethyl)-6-(1-Methyl-1H-Pyrazol-4-YL)Isoquinolin-1(2H)-One Derivatives as MTA-Cooperative Inhibitors of PRMT5 | |
| RS52799B (sr) | Dihidrogen fosfatna so antagonista prostaglandinskog d2 receptora | |
| JP2025121901A (ja) | ファルネソイドx受容体アゴニストの結晶質形態 | |
| WO2020083264A1 (zh) | 胍类衍生物及其用途 | |
| WO2021117759A1 (ja) | 含窒素芳香族複素環式基を有するヒストン脱アセチル化酵素阻害剤 | |
| JP2021512049A (ja) | カルボン酸基を含む窒素含有ベンゾ複素環化合物、その調製方法及び使用 | |
| CN107827837B (zh) | 鞘氨醇-1-磷酸受体调节剂化合物及其制备方法与应用 | |
| HK40016552B (en) | Potassium channel modulators | |
| HK40016552A (en) | Potassium channel modulators | |
| CN107501270A (zh) | 一种含有磺酰吖丙啶结构的化合物、药物组合物以及其应用 | |
| CN120774933A (zh) | 一种治疗或预防lrrk2介导的疾病的化合物 | |
| JP5449320B2 (ja) | 3−インダゾリル−4−ピリジルイソチアゾール類 | |
| BR112017004868B1 (pt) | Derivados de pirrolopirimidina como antagonistas do receptor nmda nr2b e composição farmacêutica que os compreende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18704122 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2019539923 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019014814 Country of ref document: BR |
|
| ENP | Entry into the national phase |
Ref document number: 20197024269 Country of ref document: KR Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: NC2019/0009060 Country of ref document: CO |
|
| WWP | Wipo information: published in national office |
Ref document number: NC2019/0009060 Country of ref document: CO |
|
| ENP | Entry into the national phase |
Ref document number: 2018704122 Country of ref document: EP Effective date: 20190823 |
|
| ENP | Entry into the national phase |
Ref document number: 112019014814 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190718 |
|
| WWG | Wipo information: grant in national office |
Ref document number: NC2019/0009060 Country of ref document: CO |